ÓÄÊ 616.24-088.444:616.61:612.46

Îñíîâíûå ïàòîôèçèîëîãè÷åñêèå ìåõàíèçìû ïî÷å÷íûõ ïîðàæåíèé, îáóñëîâëåííûõ

ñèíäðîìîì îáñòðóêòèâíîãî àïíîý-ãèïîïíîý ñíà: Абстракт

Ë.Ã. Äãåðÿí, Ã.À. Ïîäîñÿí, Ã.Ë. Õàíäàíÿí, À.Ê. Øóêóðÿí,

Ï.À. Çåëâåÿí

Ðàññìàòðèâàþòñÿ îñíîâíûå ïðè÷èíû ðàçâèòèÿ ïîðà-æåíèé ïî÷åê ó áîëüíûõ ñ ñèíäðîìîì

îáñòðóêòèâíîãî àïíîý-ãèïîïíîý ñíà.

Ìåäèöèíñêèé Âåñòíèê Ýðåáóíè, 2012, 2(50), 19-29

1. Gulleminault C., Dement W. eds. Sleep apnea syndromes. New York, Alan R. Liss Inc. 1978,pp.1-365.

2. Stradling J. Obstructive sleep apnoea: defini-tions, epidemiology, and natural history. Thorax

1995,50:683-9.

3. Shahar E., Whitney C., Redline S., et al. Sleep-disordered breathing and cardiovascular disease: cross

sectional results of the Sleep Heart Health Study. Am. J. Respir. Crit. Care Med.,

2001;163:19-25.

4. Stigter H., Lammers G., Rooyackers J., et al. Sleep disorders and the ability to drive, revision oflegislation. Ned Tijdschr Geneeskd 2009;153:A690.

5. McNicholas W., Bonsigore M. Management Committee of EU COST ACTION B26. Sleep apnoeaas an independent risk factor for cardiovascular disease: current evidence, basic mechanisms andresearch priorities. Eur. Respir. J., 2007;29:1:156-78.

6. Gami A., Howard D., Olson E., et al. Day-night pattern of sudden death in obstructive sleep apnea.N. Engl. J. Med., 2005;352:1206-14.

7. Pankow W., Lies A., Lohmann F., et al. Sleep-disordered breathing and hypertension. N. Engl.

J. Med., 2000;343:966-7.

8. Peppard P., Young T., Palta M., et al. Prospec-tive study of the association between sleep-

disordered breathing and hypertension. N. Engl.

J. Med., 2000;342:1378-84.

9. Robinson G., Stradling J., Davies R. Obstructive sleep apnoea/hypopnoea syndrome andhypertension. Thorax 2004;59:12:1089-94.

10. Зелвеян П.А., Ощепкова Е.В., Арабидзе Г.Г. Синдром апноэ во сне и артериальная гипертония. Тер.aрх. 1997;9:76-80.

11. Зелвеян П.А., Ощепкова Е.В., Буниатян М.С., и др. Особенности суточного профиля АД у больныхмягкой и умеренной формами артериальной гипертонией с синдромом апноэ/гипопноэ во сне. Тер.арх. 2001;9;8-13.

12. Van Houwelingen K., van Uffelen R., van Vliet

A. The sleep apnoea syndromes. Eur. Heart. J., 1999,20:12:858-66.

13. Williams A., Houston D., Finberg S., et al. Sleep apnea syndrome and essential hyperten-sion.Amer. J. Cardiol., 1985;55:1019-22.

Литература

14. Silverberg D., Oksenberg A., Radwan H., Iaina

A. Is obstructive sleep apnea a common cause ofessential hypertension? Israel. J. M. Sci.,

1995;31:527-35.

15. Silverberg D., Oksenberg A. Essential and

secondary hypertension and sleep-disorderedbreathing: a unifying hypothesis. J. Hum.

Hypertension, 1996;10:353-63.

16. Quan S., Gersh B. Cardiovascular consequences

of sleep-disordered breathing: Past, present and

future: Report of a workshop from the national

center on sleep disorders research. Circulation

2004;109:951-7.

17. Hla K., Skatrud J., Finn L., et al. The effect of

correction of sleep-disordered breathing onblood pressure in untreated hypertension. Chest.,

2002;122:4:1125-32.

18. Faulx M., Storfer-Isser A., Kirchner H., et al.

Obstructive sleep apnea is associated withincreased urinary albumin excretion. Sleep,

2007;30:923-9.

19. Fletcher E. Obstructive sleep apnea and the

kidney. J Am Soc Nephrol 1993;4:1111-21.

20. Sklar A., Chaudhary B. Reversible Proteinuriain Obstructive Sleep Apnea Syndrome. Arch.

Intern, Med., 1988;148:87-9.

21. Chaudhary B., Sklar A., Chaudhary T., et al.

Sleep apnea, proteinuria and nephrotic

syndrome. Sleep 1988;11:69-74.

22. Chaudhary B., Rehman O., Brown T.Proteinuria in patients with sleep apnea. J.

Family Practice, 1995;40:139-41.

23. Kimmel R., Miller G., Mendelson W. Sleepapnea syndrome in chronic renal disease. Am. J.

Med., 1989;86:308-14.

24. Mendelson W., Wadhwa N., Greenberg H. et al.

Effects of hemodialysis on sleep apnea

syndrome in end stage renal disease. Clinical

Nephrol., 1990;33:247-51.

25. Sklar A., Chaudhary B., Harp R. Nocturnal

urinary protein excretion rates in patients withsleep apnea. Nephron, 1989;51:35-8.

26. Praga M., Hernandez E., Andres A., et al.

Effects of body-weight loss and captopril

treatment on proteinuria associated with obesity.Nephron, 1995;70:35-41.

27. Bailey R., Lynn K., Burry A., et al. Proteinuria,

glomerulomegaly and focal glomerulosclerosis

in a grossly obese man with obstructive sleepapnea. Aust. NZ J. Med., 1989;19:473-4.

28. Fine L., Norman J. Chronic hypoxia as a

mechanism of progression of chronic kidney

diseases: from hypothesis to novel therapeutics.Kidney Int., 2008;4:867-72.

29. Mello P., Franger M., Boujaoude Z., et al. Night

and day proteinuria in patients with sleep apnea.Am. J. Kidney Dis., 2004;44:636-41.

30. Nangaku M. Chronic hypoxia and tubulointersti-

tial injury: a final common pathway to end-stagerenal failure. J. Am. Soc. Nephrol., 2006;17:17-

25.

31. Bratel T., Ljungman S., Runold M., Stenvinkel

P. Renal function in hypoxaemic chronic

obstructive pulmonary disease: effects of long-term oxygen treatment. Respir. Med., 2003;

97:308-16.

32. Kinebuchi S., Kazama J., Satoh M., et al.

Shortterm use of continuous positive airway

pressure ameliorates glomerular hyperfiltration

in patients with obstructive sleep apnoea

syndrome. Clin. Sci (Lond) 2004;107:317-22.

33. Schmidt M., Ledderhos C., Honig A. Kidney

function during arterial chemoreceptor stimula-

tion. I. Influence of unilateral renal nerve

section, bilateral cervical vagotomy, constant

artificial ventilation and carotid body che-

moreceptor inactivation. Biomed Biochim Acta

1985;44:695-709.

34. Krieger J., Imbs J., Schmidt M., et al. Renal

function in patients with obstructive sleep

apnea. Arch. Intern. Med., 1988;148:1337-40.

35. Warley A., Stradling J. Abnormal diurnal

variation in salt and water excretion in patients

with obstructive sleep apnea. Clin. Sci.,

1988;74:183-5.

36. Crabtree D., Morgan B., Skatrud J. Chemoreflex

sensitization augments sympathetic vasomotor

outflow in awake humans. Am. Rev. Respir.

Dis., 1993;147:A1015.

37. Fletcher E., Miller J., Schaaf J., et al. Urinary

cathecolamines before and after tracheostomy in

patients with obstructive sleep apnea and

hypertension. Sleep., 1987;10:35-44.

38. Xie A., Skatrud J., Puleo D., et al. Exposure to

hypoxia produces long-lasting sympatheticactivation in humans. J. Appl. Physiol, 2001;

91:1555-62.

39. Greenberg H., Sica A., Batson D., et al. Chronic

intermittent hypoxia increases sympathetic

Ë.Ã. Äãåðÿí, Ã.À. Ïîäîñÿí, Ã.Ë. Õàíäàíÿí, À.Ê. Øóêóðÿí, Ï.À. Çåëâåÿí

responsiveness to hypoxia and hypercapnia. J.

Appl. Physiol., 1999;86:298-305.

40. Cutler M., Swift N., Keller D., et al. Hypoxia-

mediated prolonged elevation of sympathetic

nerve activity after periods of intermittenthypoxic apnea. J. Appl. Physiol, 2004;96:754-

61.

41. Vgontzas A., Papanicolaou D., Bixler E., et al.

Sleep apnea and daytime sleepiness and fatigue:

Relation to visceral obesity, insulin resistance,

and hypercytokinemia. J Clin Endocrinol Metab

2000;85:1151-8.

42. Strhol K., Novak R., Singer W., et al. Insulin

levels, blood pressure and sleep apnea. Sleep

1994;17:614-8.

43. Fletcher E., Orolinova N., Bader M. Blood

pressure response to chronic episodic hypoxia:

the renin-angiotensin system. J Appl Physiol

2002;92:627-33.

44. Cortelli P., Parchi P., Sforza E., et al. Cardio-

vascular autonomic dysfunction in normotensive

awake subjects with obstructive sleep apnoea

syndrome. Clin Auton Res 1994;4:57-62.

45. Lai C., Yang C., Hsu Y., et al. Enhanced

sympathetic outflow and decreased baroreflex

sensitivity are associated with intermittent

hypoxia-induced systemic hypertension in

conscious rats. J. Appl. Physiol., 2006; 100:

1974-82.

46. Phillips B., Narkiewicz K., Pesek C., et al.

Effects of obstructive sleep apnea on endothelin-

1 and blood pressure. J Hypertens 1999;17:61-6.

47. Narkiewicz K., van de Borne P., Montano N., et

al. Contribution of tonic chemoreflex activation

to sympathetic activity and blood pressure in

patients with obstructive sleep apnea.

Circulation 1998;97:943-5.

48. Mills P., Kennedy B., Loredo J., et al. Effects of

nasal continuous positive airway pressure and

oxygen supplementation on norepinephrine

kinetics and cardiovascular responses inobstructive sleep apnea. J. Appl. Physiol.,

2006;100:343-8.49. Grote L., Kraiczi H., Hedner J. Reduced α- and

β2-adrenergic vascular response in patients with

obstructive sleep apnea. Am. J. Respir. Crit Care

Med., 2000;162:1480-7.

50. Greenberg D., Chan J., Sampson H. Endothelins

and the nervous system. Neurology 1992;42:25-

31.

51. Marasciulo F., Montagnani M., Potenza M.

Endothelin-1: the yin and yang on vascular

function. Curr Med Chem 2006;13:1655-65.

52. Haight J., Djupesland P. Nitric oxide and

obstructive sleep apnea. Sleep Breath 2003;

7:53-62.

53. Ip M., Lam B., Chan L., et al. Circulating nitric

oxide is suppressed in obstructive sleep apnea

and is reversed by nasal continuous positive

airway pressure. Am J Respir Crit Care Med

2000;162:2166-71.

54. Zhao H., Chen B., Cao J., et al. Effects of

obstructive sleep apnea style intermittent

hypoxia on endothelin-1, nitric oxide, and nitric

oxide synthase in endothelium: experiment with

human umbilical vein endothelial cells.

Zhonghua Yi Xue Za Zhi 2007 21;87:31:2189-

92.

55. Grimpen F., Kanne P., Schulz E., et al.

Endothelin-1 plasma levels are not elevated in

patients with obstructive sleep apnoea. Eur

Respir J 2000;15:320-5.

56. Jordan W., Reinbacher A., Cohrs S. et al.

Obstructive sleep apnea: plasma endothelin-1

precursor but not endothelin-1 levels are

elevated and decline with nasal continuous

positive airway pressure. Peptides 2005;

26:1654-60.

57. Jordan W., Cohrs S., Degner D. et al. Evaluation

of oxidative stress measurements in obstructive

sleep apnea syndrome. J. Neural. Transm.,

2006;113:239-54.

58. Lavie L. Obstructive sleep apnoea syndrome –an oxidative stress disorder. Sleep Med. Rev.

2003;7:35-51.

59. Cohen R. The role of nitric oxide and other

endothelium-derived vasoactive substances in

vascular disease. Prog Cardiovasc Dis 1995;

38:105-28.

60. Carlson J., Rangemark C., Hedner J. Attenuated

endothelium-dependent vascular relaxation in

patients with sleep apnoea. J Hypertens

1996;14:577-84.

61. Kato M., Roberts-Thomson P., Phillips B., et al.

Impairment of endothelium-dependent vasodila-

tion of resistance vessels in patients with

obstructive sleep apnea. Circulation 2000; 102:

2607-10.

62. Schulz R., Schmidt D., Blum A., et al. Decrea-

sed plasma levels of nitric oxide derivatives in

Îñíîâíûå ïàòîôèçèîëîãè÷åñêèå ìåõàíèçìû ïî÷å÷íûõ ïîðàæåíèé, îáóñëîâëåííûõ ñèíäðîìîì îáñòðóêòèâíîãî àïíîý-ãèïîïíîý ñíà

obstructive sleep apnoea: response to CPAP

therapy. Thorax 2000;55:1046-51.

63. Fletcher E., Bao G., Li R. Renin activity and

blood pressure in response to chronic episodic

hypoxia. Hypertension 1999;34:309-14.

64. Bostrom K., Hedner J., Melander O., et al.

Interaction between the angiotensin-converting

enzyme gene insertion/deletion polymorphism

and obstructive sleep apnoea as a mechanism for

hypertension. J Hypertens 2007;25:779-83.

65. Millman R., Redline S., Carlisle C., et al.

Daytime hypertension in obstructive sleep

apnea. Prevalence and contributing risk factors.

Chest 1991;99:861-6.

66. Kraiczi H., Hedner J., Peker Y., et al. Increased

vasoconstrictor sensitivity in obstructive sleep

apnea. J Appl Physiol 2000;89:493-8.

67. Moller D., Lind P., Strunge B., et al. Abnormal

vasoactive hormones and 24-hour blood

pressure in obstructive sleep apnea. Am J

Hypertens 2003;16:274-80.

68. Lavie L. Sleep-disordered breathing and cere-

brovascular disease: a mechanistic approach.

Neurol Clin 2005;23:1059-75.

69. Foster G., Poulin M., Hanly P. Intermittent

hypoxia and vascular function: implications for

obstructive sleep apnoea. Exp Physiol

2007;92:51-65.

70. Clausen P., Jensen J., Jensen G., et al. Elevated

urinary albumin excretion is associated with im-

paired arterial dilatory capacity in clinically

healthy subjects. Circulation 2001;103:14:1869-

74.

71. Faulx M., Larkin E., Hoit B., et al. Sex

Influences Endothelial Function in Sleep-

Disordered Breathing. Sleep 2004;27:6:1113-20.

72. Dyugovskaya L., Lavie P., Lavie L. Increased

adhesion molecules expression and production

of reactive oxygen species in leukocytes of sleepapnea patients. Am. J. Respir. Crit. Care Med.,

2002;165:934-9.

73. Dyugovskaya L., Lavie P., Lavie L. Lym-

phocyte activation as a possible measure of

atherosclerotic risk in patients with sleep apnea.Ann. N. Y. Acad. Sci., 2005;1051:340-50.

74. Altin R., Ozdemir H., Mahmutyazicioglu K., et

al. Evaluation of carotid artery wall thickness

with high-resolution sonography in obstructivesleep apnea syndrome. J. Clin. Ultrasound,

2005;33:80-6.

75. Drager L., Bortolotto L., Lorenzi M., et al. Early

signs of atherosclerosis in obstructive sleep

apnea. Am. J. Respir. Crit. Care Med., 2005;

172:613-8.

76. Saletu M., Nosiska D., Kapfhammer G., et al.

Structural and serum surrogate markers of

cerebrovascular disease in obstructive sleep

apnea (OSA): association of mild OSA with

early atherosclerosis. J Neurol., 2006;253:746-

52.

77. Schulz R., Hummel C., Heinemann S., et al.

Serum levels of vascular endothelial growth

factor are elevated in patients with obstructive

sleep apnea and severe nighttime hypoxia. Am.

J. Respir. Crit. Care. Med., 2002;165:67-70.

78. Lavie L., Kraiczi H., Hefetz A., et al. Plasma

vascular endothelial growth factor in sleep

apnea syndrome: effects of nasal continuous

positive air pressure treatment. Am. J. Respir.

Crit Care Med., 2002;165:1624-8.

79. Wessendorf T., Thilmann A., Wang Y., et al.

Fibrinogen levels and obstructive sleep apnea in

ischemic stroke. Am. J. Respir. Crit Care Med.,

2000;162:2039-42.

80. Minoguchi K., Yokoe T., Tazaki T., et al.

Increased carotid intima-media thickness and

serum inflammatory markers in obstructive

sleep apnea. Am. J. Respir. Crit. Care. Med.,

2005;172:625-30.

81. Reuben D., Wachtel T., Brown P., et al.

Transient proteinuria in emergency medical

admissions. N. Engl. J. Med., 1982;306:1031-3.

82. Faustinella F., Uzoh C., Sheikh-Hamad D., et al.

Glomerulomegaly and proteinuria in a patient

with idiopathic pulmonary hypertension. J. Am.

Soc. Nephrol., 1997;8:1966-70.

83. Krieger J., Schmidt M., Sforza E. et al. Urinary

excretion of guanosine 3:5-cyclic mono-

phosphate during sleep in obstructive sleep ap-

noea patients with and without nasal continuous

positive airway pressure treatment. Clin. Sci.,

1989;76:31-7.

84. Krieger J., Laks L., Wilcox I. et al. Atrial

natriuretic peptide release during sleep in

patients with obstructive sleep apnoea before

and during treatment with nasal continuous

positive airway pressure treatment. Clin. Sci.,

1989;77:407-11.

85. Ichioka M., Hirata Y., Inase N. et al. Changes of

circulating atrial natriuretic peptide and

Ë.Ã. Äãåðÿí, Ã.À. Ïîäîñÿí, Ã.Ë. Õàíäàíÿí, À.Ê. Øóêóðÿí, Ï.À. Çåëâåÿí

antidiuretic hormone in obstructive sleep apnea

syndrome. Respiration 1992;59:164-8.

86. Krieger J., Follenius M., Sforza E., et al. Effects

of treatment nasal continous positive airway

pressure on atrial natriuretic peptide and argi-

nine vasopressin release during sleep in patients

with obstructive sleep apnoea. Clin. Sci., 1991;

80:443-9.

87. Loute G., Pieters D., Jadot J. et al. Effect of the

variation of hematocrit on the proteinuria of a

patient with polycythemia and congenital heart

disease. Nephron 1987;46:109-11.

88. Metcalf P., Baker J., Scott A. et al. Albuminuria

in people at least 40 years old: effect of obesity,

hypertension, and hyperlipidemia. Clin Chem

1992;38:1802-8.

89. Jerums G., MacIsaac R. Treatment of mic-

roalbuminuria in patients with type 2 diabetes

mellitus. Treat Endocrinol 2002; 1:3:163-73.

90. Stokholm K., Brochner-Mortensen J., Hoilund-

Carlsen P. Increased glomerular filtration rate

and adrenocortical function in obese women. Int

J Obes 1980;4:57-63.

91. Kasiske B., Crosson J. Renal disease in patients

with massive obesity. Arch. Intern. Med., 1986;

146:1105-9.

92. Ellis P. Renal enlargement in chronic corpulmonale. J. Clin. Pathol., 1961;14:552-6.

Îñíîâíûå ïàòîôèçèîëîãè÷åñêèå ìåõàíèçìû ïî÷å÷íûõ ïîðàæåíèé, îáóñëîâëåííûõ ñèíäðîìîì îáñòðóêòèâíîãî àïíîý-ãèïîïíîý ñíà